Overview
The goal of the SPORE is to improve outcomes of lung cancer patients by addressing current challenges and by developing the next generation of therapeutic strategies.
Supported by a grant from the National Cancer Institute, the SPORE draws on Winship's strengths in basic science, translational research, and clinical research to support key translational projects.
Winship's Lung Cancer SPORE, awarded in 2019, brings together a multidisciplinary team of oncologists, immunologists, and translational researchers.
Governed by an executive committee, the SPORE team conducts activities through a Career Enhancement Program and a Developmental Research Program and is supported by close interaction with an Administrative Core, a Biostatistics and Biomedical Informatics Core, a Pathology Core, and a Biostatistics and Informatics Core. The team of investigators benefit from advice and recommendations from external and internal advisory board members regarding its progress and direction.
Suresh Ramalingam, MD discusses how the Lung SPORE will make a substantial difference in developing the next generation of therapeutic strategies for lung cancer treatment.
Winship Lung Cancer SPORE team meetings occur once a month in the Kauffman Auditorium at Winship Cancer Institute of Emory University. Disease specialists are invited to present.
Translational Projects
Winship's Lung Cancer SPORE conducts translational and innovative research to enhance the efficacy of immunotherapy and develop novel molecularly targeted approaches to overcome resistance to treatment in lung cancer. The aim is to achieve substantial improvements in the management of patients with non-small cell lung cancer through three key translation projects:
Career Enhancement Program
The Career Enhancement Program (CEP) promotes the advancement of early career lung cancer investigators by providing training and guidance for academic physician-scientists and laboratory-based scientists who wish to dedicate their efforts to translational research in the areas of diagnosis, imaging, prevention, treatment, and improvement in quality of life in lung cancer. The program also aims to enhance diversity among the lung cancer research community.
Developmental Research Program
The Developmental Research Program (DRP) pursues new and innovative research opportunities in the lung cancer field. It solicits, evaluates, and funds the most meritorious pilot projects, monitors progress twice annually, and promotes the most successful pilot projects into full projects funded by the SPORE and/or other sources.
Contact Information
For inquiries regarding Winship's Lung Cancer SPORE, please email the program coordinator.
Acknowledgement Policy
Grant support should be acknowledged for all projects, cores, and pilot projects. Each publication, press release, or other document about research supported by a National Institutes of Health award must include an acknowledgment of award support and a disclaimer such as:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P50CA217691. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Principal Investigators
Suresh S. Ramalingam, MD, FACP, FASCO
- Executive Director
- Winship Cancer Institute of Emory University
As Executive Director, Dr. Ramalingam leads the growth and development of cancer research, clinical care, and education at Winship Cancer Institute of Emory University.
Haian Fu, PhD
- Leader, Discovery & Developmental Therapeutics Program
- Winship Cancer Institute of Emory University
Dr. Fu leads a research program which is the primary driver of discovery and evaluation of novel therapeutic options for cancer patients at Winship.